Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cibelli, US
Jose Cibelli, Holden, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090137040 | METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS - Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. In one embodiment, the invention provides methods for producing activated human embryos by parthenogenesis; in another embodiment, the invention provides methods for producing activated human embryos by somatic cell nuclear transfer whereby the genetic material of a differentiated human donor cell is reprogrammed to form a diploid human pronucleus capable of directing a cell to generate the stem cells from which autologous, isogenic cells for transplantation therapy are derived. The ability to create autologous human embryos represents a critical step towards generating immune-compatible stem cells that can be used to overcome the problem of immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development. | 05-28-2009 |
| 20100024047 | Prion-free transgenic ungulates - Transgenic and cloned ungulates and particularly cloned cattle are disclosed, wherein such cattle contain a deletion or disruption of the prion gene locus and do not express functional prion protein, and are not susceptible to prion-related diseases such as bovine spongiform encephalopy or Mad Cow Disease. | 01-28-2010 |
Jose Cibelli, East Lansing, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20090092588 | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease - Methods and cell lines for cloning ungulate embryos and offspring, in particular bovines and porcines, are provided. The resultant fetuses, embryos or offspring are especially useful for the expression of desired heterologous DNAs, and may be used as a source of cells or tissue for transplantation therapy for the treatment of diseases such as Parkinson's disease. | 04-09-2009 |
| 20090104697 | Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells - An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell. | 04-23-2009 |
| 20090136464 | Methods and compositions for cell therapy - Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at a desired target, e.g., a tissue, or organ in need of cell replacement therapy. For providing cells and tissues for transplant to a non-human mammal, the cells and tissues can be isolated from a gastrulating embryo produced by same-species nuclear transfer. Histocompatible cells and tissues for transplant to a human can be isolated from a gastrulating embryo that (i) is genetically modified to be in capable of developing beyond an early stage, or (ii) is produced by cross-species nuclear transfer between a human nuclear donor cell and an enucleated recipient cell, e.g., an oocyte, of a non-human mammal, or (iii) is produced by androgenesis or gynogenesis, or from pluripotent stem cells generated from such an embryo. Methods for producing histocompatible cells and tissues for transplant to a human can also be used to produce such cells or tissues for transplant to non-human mammals. The present invention also provides model embryonic systems having defined genetic makeup that are useful for developing and testing methods for cell and tissue therapy, and for studying genetic imprinting, reprogramming, rejuvenation, and other biochemical, metabolic, and physiological phenomena associated with embryogenesis. | 05-28-2009 |
Jose B. Cibelli, East Lansing, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20100037330 | Efficient Somatic Cell Nuclear Transfer In Fish - The present disclosure provides methods of producing enucleated cells by photoablation. Such enucleated cells may be used as recipient cells for Somatic Cell Nuclear Transfer and cloning. The nuclear donor and/or enucleated recipient cells may be any fish cells, such as zebrafish, koi, or medaka fish cells. Such methods may be used to efficiently produce transgenic fish including by way of example zebrafish, koi, and medaka fish. | 02-11-2010 |
Jose Bernardo Cibelli, East Lansing, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20090028835 | HUMAN TRANSCRIPTOME CORRESPONDING TO HUMAN OOCYTES AND USE OF SAID GENES OR THE CORRESPONDING POLYPEPTIDES TO TRANS-DIFFERENTIATE SOMATIC CELLS - The identification of 101 genes upregulated or differentially expressed by mature human oocytes is provided herein. These genes and the corresponding gene products will facilitate a greater understanding of oogenesis, folliculogenesis, fertilization, and embryonic development. In addition these genes and the corresponding gene products can be used to effect dedifferentiation and/or transdifferentiation of desired somatic cells. The resultant dedifferentiated cells and somatic cells derived therefrom can be used in cell therapies such as in the treatment of cancer, autoimmunity, and other diseases wherein specific types of cells such as hematopoietic cells may be depleted because of the underlying disease or the treatment of the disease. | 01-29-2009 |